Longevity Peptides: When A Literature Looks Bigger

Epitalon: 62 Papers, Half With The Same Author

Epitalon is a synthetic tetrapeptide based on a pineal gland extract, sold as a longevity compound largely on claims about telomerase and telomere length. It has 62 records in PubMed as an exact phrase, which is small but not nothing.

Add one term to that search — the surname of the researcher who developed it, Khavinson, as an author — and 31 of them remain. Broaden to include epithalamin, the earlier pineal extract, and it is 77 of 146.

So about half the literature on this compound comes from one research programme.

This is not an allegation of misconduct and should not be read as one. Small fields are often dominated by the group that started them, and that is how new areas begin. But independent replication is the mechanism by which science removes the errors and enthusiasms of any single group, and a literature that has not been replicated elsewhere has not had that done to it.

When someone tells you epitalon is “well researched”, the accurate version is: one group has researched it a great deal.

And Zero Randomised Trials

Filter those 62 records for the randomised-controlled-trial publication type and, as with BPC-157, you get nothing. Exactly one carries any clinical-trial type at all.

One complication, stated because it cuts against the point. Widen the search to include epithalamin — the earlier pineal extract rather than the synthetic tetrapeptide — and six randomised trials appear. They are largely older Russian clinical work on the extract, not trials of the compound sold today. But six is not zero, and anyone quoting the zero should know exactly where it stops applying.

What the recent literature actually consists of, from the most recent entries:

• Telomere length in human cell lines.
• Delayed wound healing in an in vitro model.
• Telomerase activation in bovine oocytes and post-thaw embryos.
• Narrative overviews and reviews.

Cells in a dish, cattle eggs, and reviews of cells in a dish.

The telomere claim deserves its own note, because it does most of the selling. Lengthening telomeres in a cell line is a real, measurable laboratory result. It is also not obviously a thing you want done to you without qualification — unrestricted telomerase activity is a feature of cancer cells, which is precisely why the relationship between telomeres and ageing is contested rather than settled. A compound that lengthens telomeres in culture has not thereby been shown to extend a human life, and nobody has run the study that would.

MOTS-c: The Trials Do Not Give Anyone MOTS-c

MOTS-c is a mitochondrial-derived peptide with 249 records and four carrying the randomised-trial publication type. Four is not many, but it is not zero, and it is more than most of this category can claim.

Then you read them.

They are studies of circulating MOTS-c that the body produces on its own. One measures the effect of aerobic and resistance exercise on MOTS-c levels in healthy young men. One measures how repeated heat stress modulates them. One measures levels in patients with breast cancer.

Nobody in any of them is given MOTS-c. It is the outcome being measured, not the intervention. MOTS-c is being studied as a biomarker of mitochondrial and metabolic state — something the body makes that goes up and down with what you do.

So the citation on a MOTS-c product page pointing at “human studies” is usually pointing at research showing that exercise raises your own MOTS-c. Which is a real and rather good finding, and an odd argument for buying an injectable version of it.

The same logic applies to humanin, which has 497 records and four randomised entries of a similar character.

Elamipretide: What A Real Programme Looks Like

For contrast, take the mitochondrial peptide with genuine clinical development: elamipretide, also known as SS-31. 514 records and 19 randomised trials. By the standards of this field that is enormous.

What those trials study:

• Barth syndrome — a rare genetic disorder, with long-term efficacy and safety data published in Genetics in Medicine.
• Primary mitochondrial myopathy — genotype-specific effects, in the Orphanet Journal of Rare Diseases.
• Dry age-related macular degeneration — as a topical ophthalmic solution, in Ophthalmology.

Rare inherited mitochondrial disease and an eye condition. Not ageing, not performance, not energy in healthy adults.

That is what a serious programme looks like, and it is worth seeing clearly: specific diseases, defined populations, named journals, genotype analysis, long-term follow-up. It is also the reason elamipretide is not sold to consumers as an anti-ageing compound — the people developing it are trying to treat Barth syndrome.

The pattern from retatrutide and cagrilintide repeats exactly: where the evidence is real, the compound is a pharmaceutical being developed for a specific indication, and that is not the same thing as a supplement.

Three Questions That Settle Most Of This

You do not need to be a scientist to check any of the above. Each took under a minute.

1. How many randomised trials, not how many papers?

Search the compound on PubMed, then apply the randomised-controlled-trial filter. Paper count measures interest. Trial count measures whether anyone tested it.

2. Was the compound given, or measured?

The MOTS-c question. If the peptide is the outcome rather than the intervention, the study says nothing about taking it.

3. Who wrote them?

Add the developer's surname as an author term and see how much of the literature disappears. Two thirds, in epitalon's case.

Run those three on anything in this category and the picture resolves quickly. It resolves the same way almost every time, which is the honest summary of this whole section: interesting biology, thin human evidence, and a price attached to the gap.

The things with large replicated evidence for healthy ageing remain what they were — and one of them, notably, is the intervention that raises your own MOTS-c: training, with enough protein and sleep.